Paclitaxel combined with capecitabine as first‑line chemotherapy for advanced or recurrent gastric cancer

Yuan,Meiqin; Yang,Yunshan; Lv,Wangxia; Song,Zhengbo; Zhong,Haijun

doi:10.3892/ol.2014.2131

Paclitaxel combined with capecitabine as first‑line chemotherapy for advanced or recurrent gastric cancer

Authors:
- Meiqin Yuan
- Yunshan Yang
- Wangxia Lv
- Zhengbo Song
- Haijun Zhong
View Affiliations

Affiliations: Department of Chemotherapy, Zhejiang Cancer Hospital, Hangzhou, Zhejiang 310022, P.R. China
Published online on: May 9, 2014 https://doi.org/10.3892/ol.2014.2131
Pages: 351-354

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Chemotherapy is of crucial importance in advanced gastric cancer (AGC) patients, in order to obtain palliation of symptoms and improve survival. To date, no standard chemotherapy regimen has been established for AGC. The purpose of the present study was to evaluate the efficacy and toxicity of the combination regimen of paclitaxel and capecitabine (PX) as first‑line chemotherapy in patients with advanced or recurrent gastric cancer. Patients with advanced or recurrent gastric cancer who were treated with PX as first‑line chemotherapy between January 2001 and December 2012 at the Zhejiang Cancer Hospital (Hangzhou, China) were retrospectively investigated. Survival was evaluated using the Kaplan‑Meier method. In total, 36 patients were enrolled, with a median age of 53.5 years and a Karnofsky performance status (KPS) score of ≥80. A median of 4 PX cycles were administered (range, 2-8 cycles). The median progression‑free survival time was 3.7 months [95% confidence interval (CI), 2.9‑4.5 months) and the median overall survival time was 12.0 months (95% CI, 9.8‑14.1 months). From the 36 patients evaluated, one (2.8%) achieved a complete response, seven (19.4%) achieved a partial response, 24 (66.7%) exhibited stable disease and four (11.1%) exhibited progressive disease. The objective response rate was 22.2% (8/36), and the disease control rate was 88.9% (32/36). All 36 patients were assessed for treatment toxicity. Grade 3 or 4 adverse events included neutropenia (2.8% of patients), hand‑foot syndrome (2.8%) and vomiting (2.8%). No neutropenic fever or treatment‑related mortalities were observed. PX combination chemotherapy may be a valuable first‑line therapy for advanced or recurrent gastric cancer.

View Figures

View References

1	Wagner AD and Wedding U: Advances in the pharmacological treatment of gastro-oesophageal cancer. Drugs Aging. 26:627–646. 2009.
2	Bittoni A, Maccaroni E, Scartozzi M, Berardi R and Cascinu S: Chemotherapy for locally advanced and metastatic gastric cancer: state of the art and future perspectives. Eur Rev Med Pharmacol Sci. 14:309–314. 2010.
3	Catalano V, Labianca R, Beretta GD, Gatta G, De Braud F, et al: Gastric cancer. Crit Rev Oncol Hematol. 71:127–164. 2009.
4	Moore MA, Eser S, Igisinov N, Igisinov S, Mohagheghi MA, Mousavi-Jarrahi A, Ozentürk G, Soipova M, Tuncer M and Sobue T: Cancer epidemiology and control in North-Western and Central Asia - past, present and future. Asian Pac J Cancer Prev. 11:17–32. 2010.
5	Tsai JY and Safran H: Status of treatment for advanced gastric carcinoma. Curr Oncol Rep. 5:210–218. 2003.
6	Murad AM, Santiago FF, Petroianu A, Rocha PR, Rodrigues MA and Rausch M: Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer. Cancer. 72:37–41. 1993.
7	Pyrhönen S, Kuitunen T, Nyandoto P, et al: Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with nonresectable gastric cancer. Br J Cancer. 71:587–591. 1995.
8	Glimelius B, Ekstrom K, Hoffman K, Graf W, Sjoden PO, Haglund U, Svensson C, Enander LK, Linne T, Sellstrom H and Heuman R: Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer. Ann Oncol. 8:163–168. 1997.
9	Schipper DL and Wagener DJ: Chemotherapy of gastric cancer. Anticancer Drugs. 7:137–149. 1996.
10	Cascinu S, Graziano F, Cardarelli N, et al: Phase II study of paclitaxel in pretreated advanced gastric cancer. Anticancer Drugs. 9:307–310. 1998.
11	Chao Y, Li CP, Chao TY, et al: An open, multi-centre, phase II clinical trial to evaluate the efficacy and safety of paclitaxel, UFT, and leucovorin in patients with advanced gastric cancer. Br J Cancer. 95:159–163. 2006.
12	Einzig AI, Neuberg D, Remick SC, et al: Phase II trial of docetaxel (Taxotere) in patients with adenocarcinoma of the upper gastrointestinal tract previously untreated with cytotoxic chemotherapy: the Eastern Cooperative Oncology Group (ECOG) results of protocol E1293. Med Oncol. 13:87–93. 1996.
13	Sakamoto J, Morita S, Yumiba T, et al: A phase II clinical trial to evaluate the effect of paclitaxel in patients with ascites caused by advanced or recurrent gastric carcinoma: a new concept of clinical benefit response for nonmeasurable type of gastric cancer. Jpn J Clin Oncol. 33:238–240. 2003.
14	Van Cutsem E, Moiseyenko VM, Tjulandin S, et al: Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol. 24:4991–4997. 2006.
15	Park SH, Lee WK, Chung M, et al: Paclitaxel versus docetaxel for advanced gastric cancer: a randomized phase II trial in combination with infusional 5-fluorouracil. Anticancer Drugs. 17:225–229. 2006.
16	Chon HJ, Rha SY, Im CK, Kim C, Hong MH, Kim HR, An JR, Noh SH, Chung HC and Jeung HC: Docetaxel versus paclitaxel combined with 5-FU and leucovorin in advanced gastric cancer: combined analysis of two phase II trials. Cancer Res Treat. 41:196–204. 2009.
17	Ishikawa T, Sekiguchi F, Fukase Y, Sawada N and Ishitsuka H: Positive correlation between the efficacy of capecitabine and doxifluridine and the ratio of thymidine phosphorylase to dihydropyrimidine dehydrogenase activities in tumors in human cancer xenografts. Cancer Res. 58:685–690. 1998.
18	Ishikawa T, Utoh M, Sawada N, Nishida M, Fukase Y, Sekiguchi F and Ishitsuka H: Tumor selective delivery of 5-fluorouracil by capecitabine, a new oral fluoropyrimidine carbamate, in human cancer xenografts. Biochem Pharmacol. 55:1091–1097. 1998.
19	Cao S, Lu K, Ishitsuka H and Rustum YM: Antitumor efficacy of capecitabine against fluorouracil-sensitive and -resistant tumors. Proc Am Soc Clin Oncol. 16:266a1997.
20	Hong YS, Song SY, Lee SI, Chung HC, Choi SH, Noh SH, Park JN, Han JY, Kang JH, Lee KS and Cho JY: A phase II trial of capecitabine in previously untreated patients with advanced and/or metastatic gastric cancer. Ann Oncol. 15:1344–1347. 2004.
21	Kang YK, Kim TW, Chang HM, Ryu MH, Yook JH, Oh ST, Kim BS and Lee JS: A phase I/II trial of docetaxel, capecitabine, and cisplatin as a first line chemotherapy for advanced gastric cancer. Proc Am Soc Clin Oncol. 22:40662004.
22	Park YH, Ryoo BY, Choi SJ and Kim HT: A phase II study of capecitabine and docetaxel combination chemotherapy in patients with advanced gastric cancer. Br J Cancer. 90:1329–1333. 2004.
23	Cho EK, Lee WK, Im SA, Lee SN, Park SH, Bang SM, Park DK, Park YH, Shin DB and Lee JH: A phase II study of epirubicin, cisplatin and capecitabine combination chemotherapy in patients with metastatic or advanced gastric cancer. Oncology. 68:333–340. 2005.
24	Eisenhauer EA, Therasse P, Bogaerts J, et al: New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 45:228–247. 2009.
25	Kang HJ, Chang HM, Kim TW, et al: A phase II study of paclitaxel and capecitabine as a first-line combination chemotherapy for advanced gastric cancer. Br J Cancer. 98:316–322. 2008.
26	Cunningham D, Starling N, Rao S, et al; Upper Gastrointestinal Clinical Studies Group of the National Cancer Research Institute of the United Kingdom. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med. 358:36–46. 2008.
27	Webb A, Cunningham D, Scarffe JH, et al: Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer. J Clin Oncol. 15:261–267. 1997.
28	Foukakis T, Lundell L, Gubanski M, et al: Advances in the treatment of patients with gastric adenocarcinoma. Acta Oncol. 46:277–285. 2007.
29	Sawada N, Ishikawa T, Fukase Y, et al: Induction of thymidine phosphorylase activity and enhancement of capecitabine efficacy by taxol/taxotere in human cancer xenografts. Clin Cancer Res. 4:1013–1019. 1998.